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Introduction. Metastases are the most common type of malignancy involving the bone, while bone is the third 
most frequent site for metastases, after the lung and liver. In some patients, previous medical history, physical and 
laboratory examination are not conclusive to identify the primary tumor site. In such cases a bone biopsy and im-
munohistochemical analysis may contribute to the diagnosis, determination of appropriate treatment and evaluation 
of prognosis. In this study, we tried to evaluate the imunochistochemical expression in bone metastases.
Material and methods. We reviewed 125 patients, with a mean age of 63 years, treated for bone metastases in our 
institution. All patients received palliative orthopaedic surgery for bone metastatic carcinoma. Fifty-eight patients 
had already an established diagnosis of the primary tumor, while 67 patients presented metastases with an unknown 
primary tumor origin. Immunohistochemical analysis was performed to intra-operative bone biopsy specimens. The 
expression of cytokeratine 7, cytokeratin 20 and the expression of a panel of other organ-specific markers were re-
corded. In patients with a known primary tumor, we examined the relationship between the origin of metastases, as 
suggested by the cytokeratin phenotype, compared with the one indicated by the initial histological diagnosis. We 
also recorded the efficacy of organ-specific markers to identify the primary tumor origin in epithelial bone metastases 
and we evaluated the prognosis between patients with a immunohistologically determined primary tumor origin, 
with those with an undetermined one.
Results. Associations of cytokeratine 7 and cytokeratine 20 expression confirmed diagnosis in 51 out of the 58 
patients (88%) with a known primary tumor (Cohen’s K test 0.79 SE 0.80, P < 0.0005). Immunohistochemical analysis 
also contributed to establish the diagnosis of patients with an unknown primary tumor, yielding diagnosis in 35 out 
of the 67 cases (52%). Patients with an immunochistologically undetermined primary tumor site presented a statisti-
cally significant poorer prognosis.
Conclusions. Cytokeratine 7 and cytokeratine20 are useful immunochistochemical markers in determining a pre-
liminary evaluation of bone metastases. Organ-specific immunohistochemical markers have a reliable role in either 
suggesting or confirming the possible origin of metastases. An indeterminate immunohistochemical phenotype 
seems to relate to a less differentiated lesion, with a worse prognosis. 
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2Introduction
Metastasis is the most common type of malignancy 
involving the bone, whereas bone represents the third most 
frequent site for metastases, after the lung and liver [1–3]. 
Bony lesions may be the first manifestation of malignancy in 
25–30% of cases, and sometimes the only manifestation; as 
in metastatic disease of unknown origin [1]. The number of 
cancer survivors has been rising in recent years. The 5-year 
survival rate in breast and colorectal cancer is reported 
to be more than 60% and 85%, respectively. Accordingly, 
the 5-year survival rate for patients with prostate cancer is 
reported to be more than 95%. In this setting, the increase 
in the overall survival in cancer patients may result in an 
increase in the overall incidence of bone metastases [4, 5].
In general, previous medical history, physical examina-
tion, laboratory tests, and imaging modalities are usually 
sufficient to establish a diagnosis of bone metastases. Dif-
ferential diagnosis includes primary malignant bone tumors 
(i.e. sarcoma or chondrosarcoma), hematologic diseases (i.e. 
multiple myeloma or lymphoma) and osteomyelitis. Howe-
ver, in cases of occult primary malignancies, diagnosis may 
be difficult and bone biopsy and histology may be necessary 
to determine the appropriate treatment and prognosis [1]. 
Determination of the type and origin of metastatic disease 
constitutes a challenging area in pathology. A microscopical 
evaluation may reveal specific morphological features sug-
gestive of tumor lineage and origin. However, in the absence 
of distinctive characteristics, immunochistochemichal (IHC) 
evaluation may help in diagnosis. A panel of tissue- or or-
gan-specific markers is typically used. Thus, many authors 
underline the important role that cytokeratines and other 
specific markers play in the discrimination of primary tumor 
lineage and determination of metastatic disease [6–13].
In this context, aiming to provide further insights con-
cerning IHC marker expression in metastatic carcinomas, we 
reviewed bone-tissue biopsies in a series of patients with 
bone metastases. Our purpose was to evaluate the effecti-
veness of these specific markers in identifying (or verifying) 
the primary tumor site and determine if they can provide 
certain information concerning prognosis.
Materials and methods
We initially reviewed the medical files of 194 patients 
who were admitted and treated for bone metastases to our 
institution. All patients received palliative orthopaedic sur-
gery. Pathology reports from intra-operative specimens of 
bone metastases were reviewed. 35 patients were excluded, 
because their primary tumor was other than carcinoma. 
Likewise, 34 patients were excluded because of incomplete 
clinical or pathological data in their files. A total of 125 pa-
tients (75 men and 50 women) were finally evaluated. The 
mean age of primary tumor diagnosis was 58.6 years (range, 
33–86 years), while bone metastases were diagnosed at 
a mean age of 63 years (range, 39–87 years). The time lapse 
from primary diagnosis of malignancy to the development 
of bone metastases was 40 months (range 9–304 months). 
51 patients (40.5%) presented bone metastases at a point 
after the primary tumor diagnosis, while 74 patients (59.5%) 
had already bone metastases at the time of initial diagno-
sis. Histological diagnosis of the primary tumor was already 
established at the time of the bone biopsy in 58 cases. In 84 
patients (67%), pain was the only clinical sign of metastases 
development. The mean time between onset of symptoms 
and metastases detection was 6 months (range, 1–50 mon-
ths). 30 patients (24%) presented a pathological fracture. The 
mean survival after bone metastasis detection was 14 months 
(range, 1–50 months). 
An imaging work-up (plain radiographs, CT scans, MRI 
scans, bone scans) was reviewed to locate the sites of meta-
stases, the nature of the lesions and their relationship with 
the adjacent tissues. Table I and Table II show the anatomical 
distribution of bone metastases and the primary tumor 
origin in our patients. Pathology reports of biopsies from 
bone metastases were reviewed in terms of IHC analysis. 
Tumor tissues were collected during surgical treatment of 
the bone lesion, and were then fixed for 2–5 days in neutral 
buffered formalin and then processed for decalcification 
protocol and for paraffin embedding. Fixed specimens were 
decalcified in 20% EDTA in 10N NaOH at pH 7.4 from several 
days up to several weeks with intermittent shaking to make 
a sure the solution was flowing around the bone. The decal-
cification time depended on the degree of mineralisation 
and the size of the specimen. Representative 5 μm thick 
sections were mounted on a glass slide covered with 2% 
silane solution in acetone. After dewaxing in xylene and 
rehydration in ethanol, for standard histology, slides were 
stained with Hematoxylin & Eosin staining. For immuno-
istochemistry, slides were processed for antigen retrieval 
by heating in a microwave oven in 0.02 M citrate buffer, 
Table I. Anatomical distribution of bone metastases (in the case of 
multiple metastases, all sites were included; bone metastases in more 
than three sites were defined as diffuse)











3pH 6.0. After cooling, tissue sections were incubated in 3% 
perhydrol solution to block the endogenous peroxidase 
reaction. Non-specific binding was blocked by incubation in 
5% bovine serum albumin. Incubation with specific primary 
antibodies was then followed by incubation with a bioti-
nylated secondary antibody. Sections were then covered 
with DAB and counterstained with Mayer’s hematoxylin. 
Negative controls were also performed by omitting the 
primary antibody. The expression of cytokeratine 7 (CK7), 
the expression of cytokeratin 20 (CK20) and the expression 
of a panel of other organ-specific markers, according to the 
expected tissue/organ of origin, were recorded. CEA and 
CDX2 were examined for gastrointestinal adenocarcinoma, 
APS and FAP for prostate adenocarcinoma, ER, PGR, GCDFP 
for breast carcinoma, TTF1 for pulmonary adenocarcinoma, 
WT1 for renal adenocarcinoma, HEP for hepatic carcinoma, 
and TIR for thyroid adenocarcinoma.
In the patients with an already known primary tumor, 
we examined the relationship between the origin of meta-
stases, as suggested by cytokeratin phenotype (CK7/CK20), 
compared with the one indicated by the initial histological 
diagnosis. Subsequently, we examined all the patients of 
the study evaluating the relationship between the origin 
of metastases, as suggested by the organ-specific IHC mar-
kers, and the one indicated by histological diagnosis. The 
expected and actual results obtained by IHC markers have 
been assessed by Cohen’s K test, AUC ROC, sensitivity and 
specificity.
Statistical analysis was performed with SPSS v. 19. Com-
parison between the groups of patients was conducted with 
Pearson’s Chi Square Test, calculated with the Monte Carlo 
method for small samples. Cohen’s K test and ROC analysis 
were conducted to compare the estimated and effective 
values between the groups. The Kaplan-Meier survival ana-
lysis was performed, while the Breslow test was conducted 
to assess the different features of each group. 
Results
The IHC results in bone metastasis specimens from he-
patic carcinoma (2 patients; one identified by the pheno-
type CK7+/CK20+ and the other by CK7+/CK20–) and small 
intestine carcinoma (1 patient; identified by the phenotype 
CK7–/CK20–) were not significant and were excluded. Hence, 
cytokeratin expression was evaluated in 55 cases out of the 
58 cases with a known primary tumor in the Pearson’s Chi 
Square test. Results of the cytokeratin phenotype in meta-
static bone disease are shown in Table III; agreement betwe-
en the cytokeratine phenotype and the primary histology 
of already diagnosed tumors is shown in Table IV. Results 
of Cohen’s K test, AUC ROC, the sensitivity and specificity 
between expected and actual values of immunochisto-
Table II. A breakdown of the primary tumors in our patients with bone 
metastases














Biliary tract 1 0.8%
Small intestine 1 0.8%
Bladder 3 2.4%
Total 125 100%
Table III. Cytokeratin phenotype expression in bone metastases specimens according to primary tumor sites. Patients with an unknown primary tumor 
site were excluded
Metastases origin Patients (n) No. of cases responsive to CKs test CK7 CK20 Significance
Biliary tract 1 1 (100%) + +
P < 0.005
Bladder 3 3 (100%) + +
Breast 19 18 (95%) + –
P < 0.005
Uterus 3 3 (100%) + –
Esophagus 2 2 (100%) + –
Lung 5 4 (80%) + –
Stomach 2 1 (50%) – +
P = 0.03
Cervix 1 1 (100%) – +
Colon rectum 1 1 (100%) – +
P < 0.005Prostate 2 2 (100%) – –
Kidney 16 14 (87.5%) – –
4chemistry (primary tumor and metastases) are shown in 
Table V. Accordingly, patients with unknown primary tumor 
origin were excluded. The closer Cohen’s K value was to 1, 
the greater the probability that metastases came from the 
indicated site of the cytokeratin phenotype. ICH verification 
was observed in 50 out of 58 patients (86.2%) with known 
primary tumor origin. Cohen’s K agreement between the 
primary tumor histology and the IHC results of bone meta-
stases was 0.79 — SE 0.80, P < 0.0005.
In 32 out of 67 patients (48%) though, with unknown 
primary tumor origin, IHC identification was not possible; in 
the remaining 52%, IHC identification was achieved (Tab. VI). 
Table IV. Relationship between primary histological results with cytokeratin expression in bone metastases. Patients with an unknown primary tumor 
site were excluded
Agreement between primary histology & cytokeratin  
Phenotype in bone metastases
CK7+/CK20+ CK7+/CK20– CK7–/CK20+ CK7–/CK20–
Significant results Biliary tract* Lung* Colon — rectum° Kidney*
Bladder* Breast* Stomach° Prostate*
Uterus* Cervix°
Esophagus*
Not significant results Prostate Kidney Breast
Prostate Uterus
Bladder
°Pearson’s Chi Square test presented statistical significance (P < 0.05); *Pearson’s Chi Square test presented high statistical significance (P < 0.005)
Table V. Results of Cohen’s K test, AUC ROC, the sensitivity and specificity between expected and actual values of IHC (primary tumor and metastasis). 
Patients with an unknown primary tumor site were excluded
CK 7+/CK 20+ CK 7+/CK 20– CK 7–/CK 20+ CK 7–/CK 20–
Sensibility 100% 93% 100% 80%
Specificity 98% 88% 100% 93%
Cohen’s K 0.85 — SE 0.15* 0.80 — SE 0.08* 1 — SE 0.0° 0.75 — SE 0.96*
AUC ROC 0.99 ± 0.01* 0.90 ± 0.05* 1 ± 0.0# 0.87 ± 0.06*
*P < 0.001; °P < 0.05; #P > 0.05
Table VI. Primary tumor origin and organ-specific IHC markers for epithelial metastases
Primary tumor Number of 
metastases
Diagnosis of tumor origin after organ-specific IHC markers test on bone metastases
Unknown Lung Kidney Breast Liver Rectum Stomach Prostate
Unknown 67 32 12 6 7 – 4 2 4
Lung 5 3 2 – – – – – –
Kidney 16 2 – 14 – – – – –
Breast 19 2 – – 17 – – – –
Uterus 3 3 – – – – – – –
Esophagus 2 1 1 – – – – – –
Liver 2 – – – – 2 – – –
Rectum 1 – – – – – 1 – –
Stomach 2 – – – 1 – – 1 –
Cervix 1 – – – – – 1 – –
Prostate 2 – – – – – – – 2
Biliary Tract 1 1 – – – – – – –
Small Intestine 1 – – 1 – – – – –
Bladder 3 3 – – – – – – –
TOTAL 125 47 15 21 25 2 6 3 6
5A false negative ICH result was provided in 3 out of 5 cases 
(60%) with lung carcinoma. Likewise, a false negative result 
was provided in 2 out of 16 patients (12.5%) with renal car-
cinoma, and in 2 out of 19 patients with breast carcinoma 
(10.5%). The majority of patients in this series presented 
lung, renal or breast carcinoma. Table VII shows the rela-
tionship between the 1-year survival of these patients and 
their corresponding IHC expression in bone metastases. It 
should be noticed that 3 out of 4 patients (75%) with bone 
metastases from lung carcinoma that died within a year, 
had an undetermined IHC phenotype. On the other hand, 
only 4 out of 15 patients (26.6%) with IHC determined me-
tastatic renal carcinoma and 5 out of 16 patients (31.2%) 
with determined metastatic breast carcinoma died within 
a year. Overall, patients with undetermined IHC results in 
bone metastases had a worse survival rate than those with 
determined results (P = 0.007, Breslow test; Fig. 1). Gender, 
an unknown primary tumor location, and the presentation of 
a pathological fracture, were not found to be statistically signi-
ficant prognostic factors in our series (P > 0.05, Breslow test).
Discussion
Cytokeratins consist of a family of over 20 polypeptides. 
They are intermediate filament proteins in epithelial cells 
that may be used to identify epithelial differentiation, as 
their expression pattern is usually preserved in neoplastic 
cells [11, 14]. Monoclonal antibodies against cytokeratin 
polypeptides have been established to evaluate their tissue-
-specific expression. Cytokeratins have been reported to 
be effective in distinguishing between various subsets of 
primary and metastatic carcinomas in different anatomical 
sites. More specifically, many authors have studied the co-
ordinate expression of CK7 and CK20 and reported the high 
sensibility and specificity of their association [6–13]. In our 
study we found that when these markers are both positive, 
both negative or when CK7 is positive and CK20 is negative 
there is relative success in finding possible origins in finding 
possible origins for bone metastasis from carcinoma. Addi-
tionally, we observed that the combination of a negative 
CK7 and a positive CK20 was not considered as accurate in 
diagnosis (P > 0.05) as in the other cases.
A combination of CK7 and CK20 has been previously 
reported to provide effective discrimination between carci-
nomas and is often used as part of a panel with other tissue- 
or organ-specific IHC markers to establish the primary site of 
malignancy [12]. An algorithmic and probabilistic approach 
and the use of a detailed database have been recommended 
in previous reports for effective assessment [8]. In a recent 
study [12], it has been suggested that CK7+/CK20+ may re-
present the profile of urothelial carcinoma, pancreatic ductul 
adenocarcinoma, ovarian mucinous carcinoma, bladder 
adenocarcinoma, gastric adenocarcinoma or cholangio-
carcinoma. Accordingly, the CK7+/CK20– phenotype may 
indicate lung adenocarcinoma, lung small cell carcinoma, 
breast carcinoma, ovarian serous carcinoma, endometrial 
adenocarcinoma, cholangiocarcinoma, thyroid carcinoma, 
mesothelioma, pancreatic carcinoma or gastric carcinoma. 
In the same setting, CK7–/CK20+ expression may refer to 
colorectal adenocarcinoma or Merckel cell carcinoma, while 
CK7–/CK20– to prostate adenocarcinoma, renal cell carci-
noma, hepatocellular carcinoma, squamous cell carcinoma, 
adrenal cortical carcinoma or gastric adenocarcinoma [12]. 
However, it should be mentioned that difficulties in discri-
mination often occur, as the cytokeratin phenotype may be 
altered in metastatic disease as compared to the primary 
tumor origin [8].
IHC determination of the site of origin of carcinomas 
is often achievable. When a metastasis is determined to 
be a carcinoma on the basis of screening immunostains, 
a panel of tissue- or organ-specific markers can be used in an 
attempt to suggest (or confirm) the tumor origin. However, 
diverse tumor-or organ-specific ICH markers may also react 
Table VII. The table shows the survival rate of patients based on the IHC 




Results with  
IHC markers
Survival
No. pts with 
survival  
< 12 months 
No. pts with 
survival  
> 12 months
Lung Undetermined 3 –
Determined 1 1 
Kidney Undetermined 1 –
Determined 4 11
Breast Undetermined 2 1
Determined 5 11
Figure 1. Patients with undetermined results in the ICH evaluation 
of bone metastases had a poorer 1-year survival rate than those with 
the determined phenotype (P = 0.007 at Breslow test)
6with variable tumor types. In this setting, in case of meta-
static tumors of unknown origin, the use of a panel of IHC 
markers is strongly suggested [12]. In our study we used 
such a IHC panel in 67 patients who had bone metastases 
from an unknown primary origin. However, in 32 of these 
patients (47%) the tumor origin remained undetermined. An 
explanation to this may be the fact that metastatic tumors 
can change geno- or phenotype. Hence, different immu-
noprofiles of primary carcinomas and their metastasis may 
exist [15]. On the other hand, carcinomas of the unknown 
primary site represent, by themselves, a separate clinical 
entity that accounts for about 5% of all cancers [16].
The subset of patients in our study, where IHC analysis 
did not determinate the primary tumor site, were found 
to present a poorer prognosis. Diagnosis of a metastatic 
carcinoma of an unknown primary site has long been con-
sidered synonymous with poor prognosis, with a median 
overall survival time range from 6 to 13 months. Empiric 
chemotherapy is generally administered in these patients, 
while the benefit of different treatments studied compared 
with best supportive care is still unclear [17]. The expression 
of the determinate IHC phenotype in high grade tumors mi-
ght correspond to a better differentiated appearance, with 
a better prognosis. Considering these facts, even if further 
studies with wider populations are required, patients with an 
undifferentiated phenotype may have a poorer prognosis.
Conclusions
CK7 and CK20 provide effective discrimination between 
carcinomas in bone metastasis specimens. They are often 
used as part of a panel with other tissue- or organ-specific 
IHC markers to establish the primary tumor site. A combi-
nation of these markers when examined in tissue of bone 
metastases may determine the origin of the primary tumor; 
however in some patients, primary malignancy will not be 
identified. The latter patients are expected to present 
a poorer prognosis.
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